Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13412MR)

This product GTTS-WQ13412MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Gastric Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ13412MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4100MR IVTScrip™ mRNA-Anti-oxLDL, BI-204(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BI-204
GTTS-WQ12880MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OPRX-106
GTTS-WQ10313MR IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LJM716
GTTS-WQ1382MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-981
GTTS-WQ8433MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA HSP90mab
GTTS-WQ3797MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ1191MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABP 980
GTTS-WQ2225MR IVTScrip™ mRNA-Anti-VWF, aVWF81(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA aVWF81
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW